On Thursday, JPMorgan (NYSE:JPM) adjusted its stance on Edwards Lifesciences (NYSE: NYSE:EW) stock, shifting the rating from Overweight to Neutral and significantly reducing the price target to $72 from the prior $105.
This decision followed Edwards Lifesciences' recent business update, which did not meet the market's expectations, particularly concerning Transcatheter Aortic Valve Replacement (TAVR) sales figures.
The company's announcement after the market closed on Wednesday revealed that while it had completed the acquisitions of JenaValve and Endotronix, these developments were overshadowed by the TAVR sales shortfall, resulting in overall sales that did not align with consensus forecasts. The market's reaction to this news was immediate, with indications that Edwards Lifesciences' shares would face a sharp downturn.
The analyst from JPMorgan highlighted that for Edwards Lifesciences' narrative to remain compelling, it was crucial to show that new Transcatheter Mitral and Tricuspid Therapies (TMTT) products, such as Evoque and Pascal, were gaining early market traction, and that the core TAVR business was maintaining stability. However, the recent product launches, including Triclip and Evoque, may have diverted focus, contributing to the current challenges.
Despite these setbacks, positive data is still anticipated at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) meeting. Yet, with the deceleration of TAVR growth, the analyst expressed skepticism about Edwards Lifesciences achieving a 10% or higher growth rate in 2025 and 2026. Consequently, the firm has revised downward its forecasts for both TAVR sales and the overall financial performance of the company.
In other recent news, Edwards Lifesciences has seen significant developments in its operations and strategic planning. TD Cowen reaffirmed its Buy rating for the company, despite an announcement of a delayed release of Acurate US IDE trial results, now set for presentation at the American College of Cardiology in March 2025. This delay suggests a postponement in the US approval and launch of Acurate, now anticipated in the second half of 2025.
Edwards Lifesciences recently agreed to sell its Critical Care business to Becton, Dickinson, and Company for $4.2 billion. The company also plans to acquire Innovalve Bio Medical, a deal valued at around $300 million, to enhance its portfolio of therapies.
Truist Securities increased its price target for Edwards Lifesciences to $110.00, citing consistent double-digit growth and expansion opportunities as key factors supporting the valuation. However, BTIG has maintained a Neutral rating on Edwards Lifesciences shares, despite the company's strategic move to acquire Innovalve Bio Medical.
Edwards Lifesciences announced that its Senior Vice President and Principal Accounting Officer, Robert W.A. Sellers, will retire in 2024, with Andrew M. Dahl succeeding him. The company also confirmed that its SAPIEN M3 device is on track for European approval by 2025. These are among the recent developments for Edwards Lifesciences.
InvestingPro Insights
In light of JPMorgan's recent rating change for Edwards Lifesciences, current InvestingPro data and tips offer additional context for investors. With a market capitalization of $52.4 billion and a high P/E ratio of 37.21, Edwards Lifesciences is trading at a significant earnings multiple. The company's P/E ratio adjusted for the last twelve months as of Q1 2024 is slightly lower at 32.15, reflecting a more nuanced valuation when factoring in recent earnings.
Edwards Lifesciences has demonstrated resilience with a gross profit margin of 76.63% and an operating income margin of 28.84% in the same period, indicating robust profitability. Additionally, the company's liquid assets surpass short-term obligations, and cash flows can sufficiently cover interest payments, providing financial stability. Despite the challenges faced in TAVR sales, analysts predict the company will be profitable this year, and it has been profitable over the last twelve months.
InvestingPro Tips highlight that Edwards Lifesciences generally trades with low price volatility, which may appeal to investors looking for stable stock performance. Moreover, the company operates with a moderate level of debt, which can be an encouraging sign for risk-averse investors. For those seeking deeper analysis, there are additional InvestingPro Tips available, offering comprehensive insights into Edwards Lifesciences' financial health and market performance. To access these tips and enhance your investment strategy, consider using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.